Laurus Labs Limited (BOM:540222)

Market Cap	359.85B
Revenue (ttm)	55.54B
Net Income (ttm)	3.58B
Shares Out	n/a
EPS (ttm)	6.64
PE Ratio	100.43
Forward PE	61.80
Dividend	1.20 (0.18%)
Ex-Dividend Date	May 9, 2025

Volume	72,954
Average Volume	58,608
Open	671.65
Previous Close	666.20
Day's Range	666.25 - 678.75
52-Week Range	390.30 - 678.75
Beta	n/a
RSI	68.90
Earnings Date	Jul 25, 2025

About Laurus Labs

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition,...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2005
• Employees: 6,007
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540222

Financial Performance

In 2024, Laurus Labs's revenue was 55.54 billion, an increase of 10.18% compared to the previous year's 50.41 billion. Earnings were 3.58 billion, an increase of 123.18%.